Atlas Trials

Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer

Clinical trial NCT04684017 · UNKNOWN

Trial details

NCT number
NCT04684017
Sponsor
Shanghai Chest Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
SCLCAnlotinib
Start date
2019-05-01
Primary completion
2021-09-01
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.